The San Francisco Giants finaldetermination of the source of all

The deduces at&t park concerts finaldetermination of baseball tickets states the source of all distributions in 2009 will be made afteryear-end. The actual amounts and sources of the amounts for tax reportingpurposes will depend upon the Fund's investment experience during theremainder of the fiscal year and may be subject to change based on taxregulations. Thevalue of a shareholder's investment in the Fund is determined by the Fund'smarket price, which is based on the supply and demand for the Fund's shares inthe open market. A return ofcapital distribution does not necessarily reflect the Fund's investmentperformance and should not be confused with "yield," "income" or "profit."The amounts and sources of distributions reported in this notice are onlyestimates and are not being provided for tax reporting purposes. A return of capital may occur for example, when some or allof the money that you invested in the Fund is paid back to you.

EstimatedEstimated Estimated Estimated Amounts of Amounts ofAmounts ofAmounts ofCurrent CurrentYear to DateYear to Date Quarterly QuarterlyCumulativeCumulativeDistribution DistributionDistributions Distributions per share ($)per share (%)per share ($)per share (%)Net Investment Income $.17 48%$.1748%Net Realized Short-Term Capital Gains$.04 10%$.0410%Net Realized Long-Term Capital Gains$00%$0 0%Return of Capital$.15 42%$.1542%Total (per commonshare)$.36100%$.36 100%The Fund estimates that it has distributed more than its income and netrealized capital gains; therefore, a portion of your distribution may be areturn of capital at&t park events . The estimated composition of the distributions may vary from quarter toquarter because they may be impacted by future income, expenses and realizedgains and losses on securities cubs rooftop . The table includes estimated amounts and percentages for thisdistribution and the cumulative distributions paid year to date from thefollowing sources: net investment income; net realized short-term capitalgains; net realized long-term capital gains; and return of capital appliedproportionately for both this distribution and year-to-date distributions san francisco giants . However, underSection 19 of the Investment Company Act of 1940, as amended (the "1940 Act")and related Rules, the Fund may be required to indicate to shareholders thesource of certain distributions to shareholders.The following table sets forth the estimated amounts of the sources of thedistribution for purposes of Section 19 of the 1940 Act and the Rules adoptedthereunder sbc park . tax accounting rules, applicable to the Fund, the amount andcharacter of distributable income for each fiscal year can be finallydetermined only as of the end of the Fund's fiscal year.

(NYSE: CH) (the "Fund") recently announced its adoption of amanaged distribution policy in which the Fund will pay quarterly distributions(the "Distribution Policy").In connection with the policy, the Fund's Boardof Directors is pleased to report the Fund's distribution of US 36 cents pershare of common stock declared on July 10, 2009, payable on July 24, 2009, toshareholders of record at the close of business on July 14, 2009.Under U.S att park . PHILADELPHIA, July 24 /PRNewswire-FirstCall/ --The Board of Directors of theChile Fund, Inc willie mays . An estimated 4.3 million of those procedures are performedannually, King said.The FDA posted the staff analysis here willie mccovey autographed baseball . (Reporting by Lisa Richwine, editing by Tim Dobbyn) Stocks Regulatory News willie mccovey signed baseball . Doctorsinstead use a drug to widen the vessels and boost blood flow. It is designed for use in people who cannot undergo cardiacstress tests, usually done by exercising on a treadmill, toincrease blood flow to the heart for the testing. Corvue, known generically as binodenoson, is an injectionthat helps widen blood vessels so doctors can get a better lookinside the heart when they run imaging tests such as CT scans.

FDA reviewers said Corvue's risks appeared acceptable for adrug proposed to be interchangeable with adenosine att park tickets . King said Corvue patients had fewer and less severe sideeffects and no cases of a rare but serious disruption of theheart's electrical activity, a possible complication ofadenosine baseball tickets . The studies showed Corvue provided equivalent results toadenosine "while the safety and tolerability profile of(Corvue) was clearly superior," the company said cubs rooftop . Total revenue for King, maker of muscle relaxant Skelaxinand painkiller Avinza, hit nearly $1.6 billion in 2008 san francisco giants . King, in a summary prepared for the advisory panel, saidthe Corvue analysis it used was more appropriate for comparingthe two agents, and the change was made before the data wasrevealed to the researchers. Natixis Bleichroeder analyst Corey Davis said "it seems theFDA has already made up its mind not to approve the drug." Davis, in a research note, said a negative decision"wouldn't be terribly material" to the company as he estimatedjust $70 million Corvue sales by 2012 Davis has a "buy" ratingon the stock. The FDA staff said they would ask outside advisers at ameeting on Tuesday if King's results provided confidence thatCorvue and adenosine produce similar results The FDA usuallyfollows panel recommendations.

King changed its main effectiveness analysis after thecompany reviewed results from an earlier study, FDA reviewerssaid autographed baseball . The FDA was informed of the changes but did not agreewith them, the agency analysis said sbc park . The company compared Corvue to adenosine, an approvedimaging agent, in two studies of people undergoing scans oftheir hearts willie mays . King shares were down 1 percent at $9.38 in afternoontrading on the New York Stock Exchange after earlier fallingmore than 2.5 percent . "FDA is concerned that the available data do not excludethe possibility that (Corvue) results are importantly inferiorto adenosine.. results," agency reviewers said in apreliminary analysis. Food and Drug Administration reviewers said they wereweighing whether King's studies showed the product, Corvue,worked as well as another agent commonly used in imaging teststo help doctors diagnose heart disease.